Bruce Markham, President & CEO, Chief Scientific Officer and Co-founder Phrixus Pharmaceuticals, Inc.
In addition to Phrixus responsibilities, Bruce Markham serves as mentor-in-residence in the Office of Technology Transfer at the University of Michigan and on the advisory board of Cytometix. Prior to Phrixus, he was a research fellow at Pfizer in the cardiovascular area, where he brought six compounds to the clinical candidate stage and was a member of the licensing team. He began his career as an associate professor of physiology at the Medical College of Wisconsin, as well as an established investigator at the American Heart Association, and trained in molecular genetics at the University of Arizona.
Degrees: B.A., Western Michigan University; Ph.D., Michigan State University.
James Symons, VP Clinical and Regulatory Affairs
James Symons began his clinical career at Parke-Davis, later Pfizer, where he had primary responsibility for a number of programs that resulted in New Drug Application (NDA) approvals and led efforts for the submission of additional NDAs in the areas of asthma and vaginal atrophy. Symons began his career at the Jackson Laboratory, Bar Harbor, ME, where he conducted research in behavior genetics and he was part of the first program granted funds to develop mouse models of aging.
Degrees: M.S. physiological psychology, M.S. biostatistics and research design, Ph.D. epidemiologic science, University of Michigan, Ann Arbor.